Digital breast tomosynthesis in mammographic screening: false negative cancer cases in the To-Be 1 trial.

"Declarations Ethics approval and consent to participateThe study was approved by the Regional Committee for Medical and Health Research Ethics in Norway (no. 2015/424 and 13294). Permission to use data collected before and after the To-Be studies was provided by the Cancer Registry Regulation §1–9, which gives the Cancer Registry the legal right to collect and analyze personal health information from participants in BreastScreen Norway. Written informed consent was not required for this study because we used de-identified data from women who did not refuse the Cancer Registry of Norway to use their data for quality assurance and research. Consent for publicationNot applicable. Competing interestsRitse Mann is a member of the Insights into Imaging Advisory Editorial Board. He has not taken part in the review or selection process of this article. Solveig Hofvind is the head of BreastScreen Norway but has an independent fixed position at the Cancer Registry of Norway. The remaining authors declare that they have no competing interests. Competing interests Ritse Mann is a member of the Insights into Imaging Advisory Editorial Board. He has not taken part in the review or selection process of this article. Solveig Hofvind is the head of BreastScreen Norway but has an independent fixed position at the Cancer Registry of Norway. The remaining authors declare that they have no competing interests."

"Funding Open access funding provided by UiT The Arctic University of Norway (incl University Hospital of North Norway) The study is financed by the Cancer Society through Open Call 2020 (no number), the Cancer Registry of Norway, and Haukeland University Hospital (no number)."